A Phase 2 interventional study of TG-0054 combined with G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease, sponsored by GPCR Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-19.
Sponsored by GPCR Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma — 1 open to participants now, 1 under way, 1 of them phase 3. Granulocyte Colony-Stimulating Factor · Multiple Myeloma.
Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, this one is the 24th largest by enrollment, is one of 2 that started in 2015, is one of 17 in phase 2, and was the 23rd registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →1 of the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma is open now, in 1 country. Recruiting first, the newest first:
Guangzhou Gloria Biosciences Co., Ltd. · Sites in China
Ages 18–78
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 3 · Phase 4 1
First in 1999; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.
Median enrollment 38 across the 28 interventional studies. Of the 27 that completed or were terminated, 15 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 28 have an industry lead sponsor. The 10 most frequent:
GPCR Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
GPCR Therapeutics, Inc. has 4 studies filed under Multiple Myeloma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For females, one of the following criteria must be fulfilled:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. G-CSF: 10 μg/kg/day, administrated via SC injections from Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal
Drug: TG-0054 combined with G-CSF
Drug pages: BurixaforStudies of BurixaforBurixafor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Granulocyte Colony-Stimulating FactorStudies of Granulocyte Colony-Stimulating FactorGranulocyte Colony-Stimulating Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Proportion of Patients From Whom a Total Number of CD34+ Cells ≥5.0 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions
The primary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥5.0 x 10\^6 cells/kg was collected within the first 4 leukapheresis sessions. For the primary efficacy endpoint, each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.
Time frame: Day 5 to Day 8
Proportion of Patients From Whom a Total Number of CD34+ Cells ≥2.5 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions
The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥2.5 x 10\^6 cells/kg was collected within the first 4 leukapheresis sessions. Each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.
Time frame: Day 5 to Day 8
Proportion of Patients Who Mobilized the Targeted Total Number of CD34+ Cells (≥6.0 x 10^6 Cells/kg) Within 5 Leukapheresis Sessions
The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥6.0 x 10\^6 cells/kg was collected within 5 leukapheresis sessions. Each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) 5 leukapheresis sessions.
Time frame: Day 5 to Day 9
the Pharmacodynamics (PD) Following Treatment With TG-0054 When Combined With G-CSF
determine circulating CD34+ cell counts in peripheral blood
Time frame: Day 5 (1st leukapheresis session) to Day 6 (2nd leukapheresis session)
| Milestone | TG-0054 Combined With G-CSF |
|---|---|
| Started | 12 |
| Completed | 12 |
| Not completed | 0 |
The primary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥5.0 x 10\^6 cells/kg was collected within the first 4 leukapheresis sessions. For the primary efficacy endpoint, each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.
| Proportion of participants | Within 1 Leukapheresis Session | Within 2 Leukapheresis Sessions | Within 3 Leukapheresis Sessions | Within 4 Leukapheresis Sessions |
|---|---|---|---|---|
| Overall | 0.50000 (0.2109 to 0.7891) | 0.9167 (0.6152 to 0.9979) | 0.9167 (0.6152 to 0.9979) | 0.9167 (0.6152 to 0.9979) |
| Multiple Myeloma | 0.6667 (0.2993 to 0.9251) | 0.8889 (0.5175 to 0.9972) | 0.8889 (0.5175 to 0.9972) | 0.8889 (0.5175 to 0.9972) |
| Non-Hodgkin Lymphoma or Hodgkin Disease | 0.0000 (0.0000 to 0.0000) | 1.0000 (0.2924 to 1.0000) | 1.0000 (0.2924 to 1.0000) | 1.0000 (0.2924 to 1.0000) |
The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥2.5 x 10\^6 cells/kg was collected within the first 4 leukapheresis sessions. Each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.
| Proportion of patients | Within 1 Leukapheresis Session | Within 2 Leukapheresis Sessions | Within 3 Leukapheresis Sessions | Within 4 Leukapheresis Sessions |
|---|---|---|---|---|
| Overall | 0.9167 (0.6152 to 0.9979) | 0.9167 (0.6152 to 0.9979) | 0.9167 (0.6152 to 0.9979) | 0.9167 (0.6152 to 0.9979) |
| Multiple Myeloma | 0.8889 (0.5175 to 0.9972) | 0.8889 (0.5175 to 0.9972) | 0.8889 (0.5175 to 0.9972) | 0.8889 (0.5175 to 0.9972) |
| Non-Hodgkin Lymphoma or Hodgkin Disease | 1.0000 (0.2924 to 1.0000) | 1.0000 (0.2924 to 1.0000) | 1.0000 (0.2924 to 1.0000) | 1.0000 (0.2924 to 1.0000) |
The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥6.0 x 10\^6 cells/kg was collected within 5 leukapheresis sessions. Each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) 5 leukapheresis sessions.
| Proportion of patients | Within 1 Leukapheresis Session | Within 2 Leukapheresis Sessions | Within 3 Leukapheresis Sessions | Within 4 Leukapheresis Sessions | Within 5 Leukapheresis Sessions |
|---|---|---|---|---|---|
| Overall | 0.5000 (0.2109 to 0.7891) | 0.6667 (0.3489 to 0.9008) | 0.6667 (0.3489 to 0.9008) | 0.6667 (0.3489 to 0.9008) | 0.6667 (0.3489 to 0.9008) |
| Multiple myeloma | 0.6667 (0.2993 to 0.9251) | 0.8889 (0.5175 to 0.9972) | 0.8889 (0.5175 to 0.9972) | 0.8889 (0.5175 to 0.9972) | 0.8889 (0.5175 to 0.9972) |
| Non-Hodgkin Lymphoma or Hodgkin Disease | 0.0000 (0.0000 to 0.0000) | 0.0000 (0.0000 to 0.0000) | 0.0000 (0.0000 to 0.0000) | 0.0000 (0.0000 to 0.0000) | 0.0000 (0.0000 to 0.0000) |
determine circulating CD34+ cell counts in peripheral blood
| cells/µL | Pre-dose | 4h Post-infusion | 6h Post-infusion | Pre-leukapheresis | Post-leukapheresis |
|---|---|---|---|---|---|
| Day 5 (1st leukapheresis session) | 32.50 (1.00 to 123.00) | 43.50 (0.00 to 141.00) | 42.00 (1.00 to 122.00) | 60.50 (1.00 to 206.00) | 35.50 (3.00 to 119.00) |
| Day 6 (2nd leukapheresis session) | 16.00 (1.00 to 59.50) | 28.00 (14.00 to 45.00) | 20.00 (0.00 to 45.00) | 34.00 (2.00 to 70.00) | 21.00 (16.00 to 45.00) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 10 µg/kg/Day G-CSF Alone | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| 10 µg/kg/Day G-CSF + 3.14 mg/kg TG-0054 | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Overall | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Event | 10 µg/kg/Day G-CSF Alone | 10 µg/kg/Day G-CSF + 3.14 mg/kg TG-0054 | Overall |
|---|---|---|---|
| Bone painMusculoskeletal and connective tissue disorders | 2/12 | 0/12 | 2/12 |
| HypocalcaemiaMetabolism and nutrition disorders | 1/12 | 0/12 | 1/12 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 1/12 | 1/12 |
| Dry mouthGastrointestinal disorders | 0/12 | 1/12 | 1/12 |
| NauseaGastrointestinal disorders | 0/12 | 1/12 | 1/12 |
| HypokalaemiaMetabolism and nutrition disorders | 0/12 | 1/12 | 1/12 |
| Oedema peripheralGeneral disorders | 0/12 | 1/12 | 1/12 |
| Platelet count decreasedInvestigations | 0/12 | 1/12 | 1/12 |
| ParaesthesiaNervous system disorders | 0/12 | 1/12 | 1/12 |
| Age, Continuous(years) | TG-0054 Combined With G-CSF |
|---|---|
| Mean | 58 (41 to 69) |
| Sex: Female, Male(Participants) | TG-0054 Combined With G-CSF |
|---|---|
| Female | 4 |
| Male | 8 |
| Race (NIH/OMB)(Participants) | TG-0054 Combined With G-CSF |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 2 |
| White | 8 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Weight(kg) | TG-0054 Combined With G-CSF |
|---|---|
| Mean | 82.4 (54.6 to 114.0) |
| BMI(kg/m^2) | TG-0054 Combined With G-CSF |
|---|---|
| Mean | 29.3 (21.9 to 37.1) |
The record gives a start of Feb 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2017, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Burixafor · Granulocyte Colony-Stimulating Factor
GPCR Therapeutics, Inc.